Frank Rimerman Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$948K Sell
65,435
-108,948
-62% -$1.47M 0.05% 268
2026
Q1
$2.42M Buy
174,383
+113,367
+186% +$1.58M 0.16% 106
2025
Q4
$857K Sell
61,016
-47,022
-44% -$660K 0.05% 264
2025
Q3
$1.51M Buy
108,038
+13,356
+14% +$192K 0.1% 156
2025
Q2
$1.42M Buy
94,682
+39,719
+72% +$567K 0.1% 159
2025
Q1
$725K Sell
54,963
-550
-1% -$7.59K 0.06% 245
2024
Q4
$877K Sell
55,513
-117,852
-68% -$1.77M 0.06% 214
2024
Q3
$2.75M Buy
173,365
+580
+0.3% +$9.33K 0.2% 84
2024
Q2
$2.63M Buy
+172,785
New +$2.48M 0.19% 89

Other funds holding RDY

Frank Rimerman Advisors's RDY Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its Dr. Reddy's Laboratories (RDY) stake by 62% in Q2 2026, selling an estimated $1.47M and leaving 65,435 shares worth $948K. The position accounts for 0.05% of the portfolio, ranked #268.

Frank Rimerman Advisors first reported a position in RDY in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.75M in Q3 2024. 239 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Frank Rimerman Advisors held 65,435 shares of Dr. Reddy's Laboratories worth $948K as of Q2 2026.
  • Frank Rimerman Advisors sold 108,948 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $1.47M.
  • Dr. Reddy's Laboratories made up 0.05% of Frank Rimerman Advisors's portfolio in Q2 2026, its #268 holding.
  • Frank Rimerman Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2024 and has held it in 9 quarters since.
  • Frank Rimerman Advisors's Dr. Reddy's Laboratories position peaked at $2.75M in Q3 2024.
  • 239 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.